Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
89.65
+2.32 (2.66%)
At close: Dec 5, 2025, 4:00 PM EST
89.00
-0.65 (-0.73%)
After-hours: Dec 5, 2025, 6:37 PM EST
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Protagonist Therapeutics stock have an average target of 86.44, with a low estimate of 73 and a high estimate of 102. The average target predicts a decrease of -3.58% from the current stock price of 89.65.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $96 → $98 | Strong Buy | Maintains | $96 → $98 | +9.31% | Nov 10, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $68 → $81 | Buy | Maintains | $68 → $81 | -9.65% | Nov 7, 2025 |
| Barclays | Barclays | Buy Maintains $72 → $88 | Buy | Maintains | $72 → $88 | -1.84% | Nov 7, 2025 |
| Citizens | Citizens | Buy Maintains $69 → $102 | Buy | Maintains | $69 → $102 | +13.78% | Nov 7, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $76 → $88 | Strong Buy | Maintains | $76 → $88 | -1.84% | Oct 28, 2025 |
Financial Forecast
Revenue This Year
66.12M
from 434.43M
Decreased by -84.78%
Revenue Next Year
262.15M
from 66.12M
Increased by 296.47%
EPS This Year
-1.97
from 4.23
EPS Next Year
-0.65
from -1.97
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 271.9M | 551.3M | ||||
| Avg | 66.1M | 262.2M | ||||
| Low | 37.8M | 19.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -37.4% | 733.7% | ||||
| Avg | -84.8% | 296.5% | ||||
| Low | -91.3% | -70.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.32 | 5.29 | ||||
| Avg | -1.97 | -0.65 | ||||
| Low | -2.28 | -2.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.